Page last updated: 2024-12-09

1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea is a **complex organic compound** that can be synthesized in the lab but isn't a widely known or studied molecule with established importance in research.

There's a good chance this specific compound hasn't been extensively researched, and its significance would depend on the context and goals of the research.

However, we can analyze the structure and speculate on potential reasons for its importance:

* **Thiourea Derivatives:** Thioureas are a class of organic compounds with the general formula R₁R₂NC(=S)NR₃R₄. They exhibit a wide range of pharmacological and biological activities, including anti-inflammatory, antimicrobial, anticancer, and antioxidant properties.

* **Furan Ring:** The presence of a furan ring, a five-membered heterocyclic ring with one oxygen atom, is common in naturally occurring compounds and synthetic drugs. Furan derivatives can exhibit various biological activities, including antitumor, antiviral, and antifungal properties.

* **Aromatic Ring:** The 3-methylphenyl group is a benzene ring with a methyl substituent at position 3. Aromatic rings are often found in organic compounds with biological and pharmacological activities, and they contribute to the molecule's structure and interactions with biological targets.

Therefore, the specific combination of thiourea, furan, and aromatic ring functionalities in this compound makes it a potential candidate for studying:

* **Synthesis and characterization of new thiourea derivatives.**
* **Biological activities of thiourea derivatives with a furan ring.**
* **Structure-activity relationships in thiourea-based drug development.**

However, it's crucial to remember that without specific information about the research context, it's impossible to definitively state why 1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea is significant.

**To gain a deeper understanding of its importance, you would need to know:**

* **The specific research area:** What field of research is this compound being studied in (e.g., medicinal chemistry, materials science, etc.)?
* **The research objectives:** What is the goal of the research involving this compound?
* **The experimental results:** What are the findings from the research involving this compound?

Without this context, it's difficult to assess the importance of this specific compound.

Cross-References

ID SourceID
PubMed CID844572
CHEMBL ID1602060
CHEBI ID114432

Synonyms (15)

Synonym
smr000200869
MLS000582329
AK-968/41926334
2-(2-furoyl)-n-(3-methylphenyl)hydrazinecarbothioamide
STK449785
2-(furan-2-ylcarbonyl)-n-(3-methylphenyl)hydrazinecarbothioamide
CHEBI:114432
AKOS003260429
1-(furan-2-carbonylamino)-3-(3-methylphenyl)thiourea
HMS2460H24
CHEMBL1602060
1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea
Q27195833
sr-01000288411
SR-01000288411-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
furoic acidA monocarboxylic acid that consists of a furan ring having a single carboxylic acid group on any ring position and derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency26.85450.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency20.59620.004110.890331.5287AID504467
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency0.67020.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency12.49320.036619.637650.1187AID2100
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]